This article covers stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
The word alone makes you shiver.
Every year, there are approximately 230,000 women diagnosed with breast cancer in the United States. According to the National Cancer Institute, of these women, about 75% test positive for HER2 (IHC 1+, 2+ or 3+). Out of these, only 25% of all breast cancer patients, those with HER2 3+ disease, are eligible for Herceptin®, from Roche (OTCQX:RHBY) and Genentech, which had revenues of over $6 billion in 2012.
The remaining 50% of low HER 2 expressing patients, or those that...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|